Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms

scientific article published on June 1992

Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1365-2362.1992.TB01482.X
P698PubMed publication ID1633836

P2093author name stringMustajoki P
Tenhunen R
Matikainen E
Seppäläinen AM
Timonen K
Gorchein A
P2860cites workRepression of the Overproduction of Porphyrin Precursors in Acute Intermittent Porphyria by Intravenous Infusions of HematinQ37491123
Effect of hematin in porphyric neuropathyQ40113953
Neuropharmacology of delta-aminolaevulinic acid. II. Effect of chronic administration in miceQ41578390
Determination of delta-aminolaevulinic acid in biological fluids by gas-liquid chromatography with electron-capture detectionQ42868310
Tissue uptake of o-aminolaevulinic acidQ44800562
Determination of delta-aminolevulinic acid in plasmaQ45213072
Effects of haem arginate on variegate porphyriaQ46120537
P433issue6
P304page(s)407-411
P577publication date1992-06-01
P1433published inEuropean Journal of Clinical InvestigationQ15745208
P1476titleSustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms
P478volume22

Reverse relations

cites work (P2860)
Q34520894Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement
Q73822695Effects of fractionated 5-aminolevulinic acid administration on tissue levels of protoporphyrin in vivo
Q45248914Fluorescence imaging technique: diagnostic and therapeutic interest in gynecology
Q92046226Heme biosynthesis and the porphyrias
Q28200784Heme deficiency in Alzheimer's disease: a possible connection to porphyria
Q54133753Hemodynamic effects of 5-aminolevulinic acid in humans
Q42478276Mitochondrial energetic defects in muscle and brain of a Hmbs-/- mouse model of acute intermittent porphyria
Q33849564Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria
Q35976204Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy
Q36850059Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues
Q42546478Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood
Q35210457Photodynamic therapy for pancreatic carcinoma: experimental and clinical studies.
Q36080027Photodynamic therapy using 5-aminolaevulinic acid for experimental pancreatic cancer--prolonged animal survival
Q34407455Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study
Q73095011Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolevulinic acid
Q89563680Preanesthetic severe postural hypotension following 5-aminolevulinic acid pretreatment in patients for photodynamic diagnosis-assisted urological surgery
Q33610809The cutaneous porphyrias: a review. The British Photodermatology Group
Q73458945The importance of fluorescence distribution and kinetics of ALA-induced PpIX in the bladder in photodynamic therapy